Show Notes
In this episode, Professor Leon De Windt, co-founder of miRabilis Therapeutics at Maastricht University explains his journey of working with micro – RNA’s of the heart. He shares his path from America to Utrecht to now Maastricht and the different research carried out throughout. How are non – coding RNA’s linked to regenerative medicine? And why did COVID help in the credibility of these mRNA’s? Other than answering these questions, Professor De Windt shares his advice on entrepreneurship as well as his role in the European TRAIN-HEART association.
More from Biomed Unleashed
What does it take to guide scientific research and higher education at one of the world's best young universities?
What does it take to build one of Europe’s leading research institutes in Regenerative Medicine? In this inspiring conversation, we speak with Professor Clemens van Blitterswijk, a pioneer in tissue engineering and founder of the MERLN Institute for Technology-Inspired Regenerative Medicine in Maastricht, the Netherlands. The conversation touches on many turning points: building companies during crises, navigating the choice between academia and business, and leading a remarkable transfer of sixteen colleagues to establish a new research institute. Clemens reflects on the right time to commercialize discoveries and how coincidental findings can lead to breakthroughs in top journals. He shares insights on helping startups through RegMed XB and the delicate art of knowing when to push forward and when to stop. We also discussed why art and science are more closely related than we think. From biomaterials that grow bone to Clemens’ vision for high-throughput technologies, this interview reveals a scientist-entrepreneur who has not only advanced regenerative medicine but also built bridges between universities, startups, and patients – pushing regenerative medicine field forward.
What does it take to lead the future of regenerative medicine? Professor Martijn van Griensven shared the experiences that have shaped his journey from his early days as Germany’s youngest professor to his current work as a leading mind in biomedical research and head of the cBITE department at the MERLN Institute. We explored how bones heal, and why sometimes they don’t, and what role the immune system plays when regeneration breaks down. We dove into the molecular world of RNA therapies and their potential to modulate immune responses and help tissues rebuild themselves. We talked about the practical challenges of bringing these therapies into the clinic, the role of AI in tailoring treatments to each patient, and what the future might hold. For Professor van Griensven, it’s not just about molecules and machines, it’s about curiosity, perseverance, and asking the right questions.
How do you commercialize regenerative medicine, and why is it so challenging? What does it take to build a successful biotech startup? And are revolutionary regenerative medicine solutions closer than we think?
How do you get hold of the viruses and, with their help, cure some of the deadliest diseases known to humanity?